BioFocus and Ono Sign a Drug Discovery Agreement in the Field of CNS Disorders
Complete the form below to unlock access to ALL audio articles.
Galapagos NV has announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. (Osaka Japan) have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders.
Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client. Financial details were undisclosed.
“We are delighted to have this new agreement, which is the first drug discovery program with this, a most valued, client” said Dr. Chris Newton, SVP Galapagos Services and Managing Director of BioFocus.
Dr. Newton continued, “This project plays to BioFocus historic strengths and the expanding breadth and depth of this partnership is testament to a tried and trusted relationship.”
Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of Ono commented: “We have the highest regard for the BioFocus’ comprehensive drug discovery platform. This collaboration will strengthen Ono’s drug discovery capability in the field of CNS disorders with significant unmet medical needs and we are expecting that innovative drugs will be created through this collaboration.”
